Liposomes as nanomedical devices.
Liposomes as nanomedical devices.
复制标题
DOI：
10.2147/ijn.s68861
复制
发表时间：
2015
影响因子：
8
通讯作者：
Molinari A
中科院分区：
文献类型：
--
作者：
Bozzuto G;Molinari A
自 20 世纪 60 年代发现以来，人们对脂质体进行了深入研究，并且继续构成一个深入研究的领域。脂质体因其生物学和技术优势而受到重视，被认为是迄今为止已知的最成功的药物载体系统。目前已经取得了显着的进展，脂质体的一些生物医学应用要么正在进行临床试验，要么即将投放市场，或者已经被批准供公众使用。在这篇综述中，我们简要分析了脂质体的功效如何取决于其成分的性质及其大小、表面电荷和脂质组织。此外，我们还讨论了脂质体的理化性质对其与细胞的相互作用、半衰期、进入组织的能力以及体内最终命运的影响。最后，我们描述了一些为克服“第一代”脂质体以及市场上和临床试验中基于脂质体的药物的局限性而开发的策略。
Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.